201864-00-8

Basic information

• Product Name: (S)-2-amino-3-(4-chlorophenyl)propan-1-ol
• Synonyms: (S)-2-amino-3-(4-chlorophenyl)propan-1-ol;(S)-b-AMino-4-chlorobenzenepropanol;(S)-beta-Amino-4-chlorobenzenepropanol;2(S)-Amino-3-(4-chlorophenyl)propanol
• CAS NO: 201864-00-8
• Molecular Formula: C₉H₁₂ClNO
• Molecular Weight: 185.65068
• Mol File: 201864-00-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-2-amino-3-(4-chlorophenyl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-amino-3-(4-chlorophenyl)propan-1-ol(201864-00-8)
• EPA Substance Registry System: (S)-2-amino-3-(4-chlorophenyl)propan-1-ol(201864-00-8)

Safety Data

• Hazardous Substances Data: 201864-00-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-amino-3-(4-chlorophenyl)propan-1-ol is used as a precursor in the synthesis of various pharmaceuticals due to its unique molecular structure and reactivity. Its ability to be modified and incorporated into a range of compounds makes it a valuable starting material for developing new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, (S)-2-amino-3-(4-chlorophenyl)propan-1-ol is utilized as a precursor for the development of new agrochemicals. Its structural properties allow for the creation of compounds with specific pesticidal, herbicidal, or fungicidal activities, contributing to the advancement of crop protection and management strategies.
Used in Organic Synthesis:
(S)-2-amino-3-(4-chlorophenyl)propan-1-ol is used as a reagent in organic synthesis, where its functional groups can be manipulated to produce a variety of target molecules. This versatility makes it a valuable tool for chemists working on the development of new organic compounds for various applications, including materials science, pharmaceuticals, and specialty chemicals.
Used in Building Blocks for Compound Production:
(S)-2-amino-3-(4-chlorophenyl)propan-1-ol (S)-2-amino-3-(4-chlorophenyl)propan-1-ol serves as a building block for the production of various compounds across different industries. Its unique structure and functional groups enable the creation of a wide range of molecules with diverse properties and applications, making it an essential component in the synthesis of complex organic molecules.

Upstream product

• 68759-85-3 para-chlorophenylalanine methyl ester 
• 35373-63-8 (R,S)-2-amino-3-p-chlorophenyl-1-propanol 
• 14173-39-8 p-chlorophenylalanine 

Downstream Products

• 1407180-51-1 (4S)-2-isopropyl-4-(4-chlorophenylmethyl)-1,3-oxazolidine 

Relevant articles and documents

SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS

Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis

Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are the enzymatically active chitinases that have been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis. The clinical and preclinical data suggest that pharmacological inhibition of CHIT1 might represent a novel therapeutic approach in IPF. Structural modification of an advanced lead molecule 3 led to the identification of compound 9 (OATD-01), a highly active CHIT1 inhibitor with both an excellent PK profile in multiple species and selectivity against a panel of other off-targets. OATD-01 given orally once daily in a range of doses between 30 and 100 mg/kg showed significant antifibrotic efficacy in an animal model of bleomycin-induced pulmonary fibrosis. OATD-01 is the first-in-class CHIT1 inhibitor, currently completed phase 1b of clinical trials, to be a potential treatment for IPF.

SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS

Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Electronic effects of aryl-substituted bis(oxazoline) ligands on the outcome of asymmetric copper-catalysed C-H insertion and aromatic addition reactions

The effect of the modification of bis(oxazoline) ligands on the outcome of copper-catalysed C-H insertion and aromatic addition reactions is described. In general, these reactions display minimum sensitivity in terms of enantiocontrol to variation of the electronic properties of the aryl moiety of the ligand however, some influence is observed for C-H insertions employing naphthyl-substituted bis(oxazolines) and for aromatic addition reactions of biphenyl diazo ketone substrates. The synthesis of the modified bis(oxazolines), which include four novel structures, is also described.

New thiazole carboxamides as potent inhibitors of Akt kinases

A new series of 2-substituted thiazole carboxamides were identified as potent pan inhibitors against all three isoforms of Akt (Akt1, Akt2 and Akt3) by systematic optimization of weak screening hit N-(1-amino-3-phenylpropan-2-yl)- 2-phenylthiazole-5-carboxamide (1). One of the most potent compounds, 5m, inhibited the kinase activities of Akt1, Akt2 and Akt3 with IC50 values of 25, 196 and 24 nM, respectively. The compound also potently inhibited the phosphorylation of downstream MDM2 and GSK3β proteins, and displayed strongly antiproliferative activity in prostate cancer cells. The inhibitors might serve as lead compounds for further development of novel effective anticancer agents.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.